Jennifer Swainson

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review

Sarah A. Smith, Haseeb Mohammad, Lik Hang N Lee, Liz Dennett et autres

ca, nl (code pays fourni par la source)

Interpreting Adverse Events of Somnolence With Lemborexant in Clinical Trials (P6-14.012)

Margaret Moline, Christopher J. Reaume, Dinesh Kumar, Kate Pinner et autres

To discuss interpreting treatment-emergent adverse events of somnolence (TEAE-S) from 2 large phase 3 studies of lemborexant (LEM), a dual orexin-receptor antagonist approved to treat adults with insomnia.

jp, ca (code pays fourni par la source)

Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis

Isis Lunsky, Gilmar Gutierrez, Xena Wang, Andrea Zhuang et autres

INTRODUCTION: Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing …

ca (code pays fourni par la source)

Are the current safety measures for the treatment of depression with esketamine sufficient?

Kyle Valentino, Kayla M. Teopiz, Christine E. Dri, Jennifer Swainson et autres

1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...

ca (code pays fourni par la source)

A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program

Ian Stefanuk, Kaitlin Chivers-Wilson, Rakesh Jetly, A. Khullar et autres

Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans, and the presence of multiple conditions requires innovative treatment approaches. The Newly Institute in Calgary, Alberta, Canada, has introduced a novel intervention combining sublingual …

ca (code pays fourni par la source)

Interpreting Adverse Events of Somnolence With Lemborexant in Clinical Trials

M. Moline, C.J. Reaume, D. Kumar, Kate Pinner et autres

us, gb, ca (code pays fourni par la source)

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

Jennifer Swainson, Elisa Brietzke, Atul Khullar, Roger S. McIntyre et autres

There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation …

ca (code pays fourni par la source)

Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review

Reinhard Janssen‐Aguilar, Shakila Meshkat, Huda Al-Shamali, Argyrios Perivolaris et autres

Background: Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates …

ca, nl (code pays fourni par la source)

Evolving Psychotherapeutic Approaches for PTSD: Beyond the Fear-Based Model.

Lisa Burback, Olga Winkler, Rakesh Jetly, Jennifer Swainson et autres

Traditional trauma-focused psychotherapies (TFPs) were developed based on an anxiety disorder model of posttraumatic stress disorder (PTSD). However, PTSD is a more complex disorder with heterogeneous onset, presentation, trajectory, and treatment responsivity. As half of treated patients do not respond to first-line …

ca, nl, us (code pays fourni par la source)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review

Shakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, Guoqiang Li et autres

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potential therapeutic options for psychiatric symptoms due to their effects on mood and behavior. However, their use has been primarily for metabolic diseases, and limited research has evaluated their psychiatric efficacy. This …

ca, au, nl (code pays fourni par la source)

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee

Gilmar Gutiérrez, Gustavo Vázquez, Nisha Ravindran, Raymond W. Lam et autres

Background: Intranasal (IN) esketamine has become an effective and well-tolerated therapeutic option for the management of treatment-resistant depression within major depressive disorder (MDD-TRD). Despite these promising benefits, given the prevalence of ketamine abuse, concerns remain over the addiction liability that may be …

ca (code pays fourni par la source)

A framework to assess risks for non-medical use of psychedelics: The liability for abuse of psychedelics questionnaire (LAPQ)

Jennifer Swainson, Cláudio N. Soares, Roger S. McIntyre, Gilmar Gutiérrez et autres

: As psychedelic research moves forward, trial design could benefit from assessments of potential risks of treatment. One such risk is future abuse or misuse of the drug or other drugs of abuse. Like the ketamine literature, psychedelic studies to date have …

ca (code pays fourni par la source)